Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo

Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo

In order to enable <sup>18</sup>F- and <sup>177</sup>Lu-labelling within the same molecule, we introduced a silicon-based fluoride acceptor (SiFA) into the hexa-D-glutamate chain of DOTA-PP-F11N. In addition, minigastrin analogues with a prolonged as well as <i>γ</i&...

Full description

Bibliographic Details
Main Authors: Nadine Holzleitner, Thomas Günther, Roswitha Beck, Constantin Lapa, Hans-Jürgen Wester
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Pharmaceuticals
Subjects:
cholecystokinin-2 receptor (CCK-2R)
cholecystokinin-B receptor (CCK-BR)
medullary thyroid cancer (MTC)
minigastrin analogues
radiohybrid
rhCCK
Online Access:https://www.mdpi.com/1424-8247/15/12/1467

Internet

https://www.mdpi.com/1424-8247/15/12/1467

Similar Items